Display options
Cite
Meng MB, Jiang C, Tian LJ, et al. Late course accelerated hyperfractionation radiotherapy for locally advanced esophageal squamous cell carcinoma. Thorac Cancer. 2013;4(2):174-185doi: 10.1111/j.1759-7714.2012.00166.x.
Meng, M. B., Jiang, C., Tian, L. J., Liu, C. L., Zhuang, H. Q., Chen, Z. J., Song, Y. C., Wang, J., Pang, Q. S., Zhao, L. J., Yuan, Z. Y., & Wang, P. (2013). Late course accelerated hyperfractionation radiotherapy for locally advanced esophageal squamous cell carcinoma. Thoracic cancer, 4(2), 174-185. https://doi.org/10.1111/j.1759-7714.2012.00166.x
Meng, Mao-Bin, et al. "Late course accelerated hyperfractionation radiotherapy for locally advanced esophageal squamous cell carcinoma." Thoracic cancer vol. 4,2 (2013): 174-185. doi: https://doi.org/10.1111/j.1759-7714.2012.00166.x
Meng MB, Jiang C, Tian LJ, Liu CL, Zhuang HQ, Chen ZJ, Song YC, Wang J, Pang QS, Zhao LJ, Yuan ZY, Wang P. Late course accelerated hyperfractionation radiotherapy for locally advanced esophageal squamous cell carcinoma. Thorac Cancer. 2013 May;4(2):174-185. doi: 10.1111/j.1759-7714.2012.00166.x. PMID: 28920199.
Copy Download .nbib Format: NLM
Share it on

Thorac Cancer. 2013 May;4(2):174-185. doi: 10.1111/j.1759-7714.2012.00166.x.

Late course accelerated hyperfractionation radiotherapy for locally advanced esophageal squamous cell carcinoma.

Thoracic cancer

Mao-Bin Meng, Chao Jiang, Li-Jun Tian, Chun-Lei Liu, Hong-Qing Zhuang, Zhong-Jie Chen, Yong-Chun Song, Jun Wang, Qing-Song Pang, Lu-Jun Zhao, Zhi-Yong Yuan, Ping Wang

Affiliations

  1. Department of Radiation Oncology, Tianjin Medical University Cancer Hospital & Institute, Tianjin, China.
  2. Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Hospital & Institute, Tianjin, China.
  3. Cyberknife Center, Tianjin Medical University Cancer Hospital & Institute, Tianjin, China.

PMID: 28920199 DOI: 10.1111/j.1759-7714.2012.00166.x

Abstract

BACKGROUND: Late course accelerated hyperfractionation radiotherapy (LCAHR) is used as a standard treatment option for locally advanced esophageal squamous cell carcinoma (LAESCC) in China, but concerns remain regarding its efficacy and safety. The purpose of this paper was to evaluate the efficacy and safety of LCAHR. The comparisons examined were as follows: LCAHR versus conventional fractionation radiotherapy (CFR) and LCAHR plus chemotherapy (CT) versus LCAHR alone.

METHODS: We searched the Cochrane Library, MEDLINE, EMBASE, CENTRAL, CBMdisc, and CNKI, as well as employing manual searches. The primary end points were survival and local control. The second end point was toxicities.

RESULTS: Based on search criteria, we found 29 trials involving 3187 patients. Our results showed that LCAHR, compared with CFR, improved the survival and local control, and was, thus, more therapeutically beneficial. Further analysis revealed that LCAHR plus CT proved to be better for patients' survival and local control compared to LCAHR alone. Acute toxicities were increased rather than late toxicities.

CONCLUSIONS: There was a significant survival and local control benefit of LCAHR over CFR, as well as LCAHR plus CT over LCAHR alone. Considering the strength of the evidence, the results of this study indicate that this regimen would be a new promising modality worth further investigation.

© 2012 Tianjin Lung Cancer Institute and Wiley Publishing Asia Pty Ltd.

Keywords: Esophageal squamous cell carcinoma; late course accelerated hyperfractionation radiotherapy; meta-analysis; randomized controlled trial

Publication Types